198 related articles for article (PubMed ID: 8944075)
1. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
[TBL] [Abstract][Full Text] [Related]
3. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo.
Howe SR; Gottardis MM; Everitt JI; Walker C
Endocrinology; 1995 Nov; 136(11):4996-5003. PubMed ID: 7588234
[TBL] [Abstract][Full Text] [Related]
4. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.
Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C
Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178
[TBL] [Abstract][Full Text] [Related]
5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.
Glace L; Grygielko ET; Boyle R; Wang Q; Laping NJ; Sulpizio AC; Bray JD
Steroids; 2009; 74(13-14):1015-24. PubMed ID: 19665469
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
8. Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro.
Hodges LC; Bergerson JS; Hunter DS; Walker CL
Toxicol Sci; 2000 Apr; 54(2):355-64. PubMed ID: 10774817
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
10. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
11. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
[TBL] [Abstract][Full Text] [Related]
12. The estrogen receptor's involvement in osteoblasts' adaptive response to mechanical strain.
Damien E; Price JS; Lanyon LE
J Bone Miner Res; 1998 Aug; 13(8):1275-82. PubMed ID: 9718196
[TBL] [Abstract][Full Text] [Related]
13. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.
Houston KD; Copland JA; Broaddus RR; Gottardis MM; Fischer SM; Walker CL
Cancer Res; 2003 Mar; 63(6):1221-7. PubMed ID: 12649180
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
16. Does raloxifene inhibit the growth of uterine fibroids?
Palomba S; Zullo F; Orio F; Lombardi G
Fertil Steril; 2004 Jun; 81(6):1719-20; author reply 1720-1. PubMed ID: 15193512
[No Abstract] [Full Text] [Related]
17. Tamoxifen-stimulated growth of human endometrial carcinoma.
Jordan VC; Gottardis MM; Satyaswaroop PG
Ann N Y Acad Sci; 1991; 622():439-46. PubMed ID: 1905895
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
20. Growth response of colon cancer cell lines to selective estrogen receptor modulators.
Picariello L; Fiorelli G; Martineti V; Tognarini I; Pampaloni B; Tonelli F; Brandi ML
Anticancer Res; 2003; 23(3B):2419-24. PubMed ID: 12894523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
